|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/26 | |
| A61K 39/395 | |||
| A61P 3/10 | |||
| C07K 16/24 | |||
| A61K 39/00 |
| (11) | Number of the document | 3139948 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15720982.6 |
| Date of filing the European patent application | 2015-05-05 | |
| (97) | Date of publication of the European application | 2017-03-15 |
| (45) | Date of publication and mention of the grant of the patent | 2020-03-04 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2015/059811 |
| Date | 2015-05-05 |
| (87) | Number | WO 2015/169789 |
| Date | 2015-11-12 |
| (30) | Number | Date | Country code |
| 201461989841 P | 2014-05-07 | US | |
| 14169596 | 2014-05-23 | EP | |
| 14189732 | 2014-10-21 | EP |
| (72) |
COPPIETERS, Ken, DK
VON HERRATH, Matthias, US
BOURSALIAN, Tamar, US
|
| (73) |
Novo Nordisk A/S,
Novo Allé, 2880 Bagsvęrd,
DK
|
| (54) | TREATMENT OF DIABETES TYPE 1 USING GLP-1 AND ANTI-IL-21 |
| TREATMENT OF DIABETES TYPE 1 USING GLP-1 AND ANTI-IL-21 |